Skin substitutes provide temporary or permanent wound closure and protect the wound from infection, further damage and water loss, and reduce pain. They also facilitate the growth of the normal skin over the wound. Rising incidences of burn injuries is expected to drive the market. For instance, according to the World health organization, an estimated 180 000 deaths every year are caused by burns – the vast majority occur in low- and middle-income countries.
Also, the presence of novel approaches in the treatment of burns is expected to drive the market. For instance, 3D bioprinting, a transformative technology for the reconstruction of burn wounds is the recent approach which enables accurate placement of cell types and allows precise and reproducible fabrication of constructs which replaces the injured or damaged sites. Thus, its use for wound reconstruction will lead to a paradigm shift in patient outcomes. However, there are several limitations to the commercially available skin substitutes, like reduced vascularization, poor mechanical integrity, failure to integrate, scarring, and immune rejection .
Market Dynamics
Drivers
- Growing prevalence of diabetes
- Rising chronic skin diseases
- Increasing geriatric population
- Increasing number of burn injuries
- Advancement in Technology
Restraints
- High cost of skin substitutes
- Limitations to existing skin substitutes products
Market Segmentation
Rise in preference for acellular skin substitutes to implant-based skin surgery is expected to drive the growth of the global skin substitutes market. For instance, the American Society of Plastic Surgeons in 2012, reported that more than 50% surgeons in the US have preferred acellular matrix for skin surgeries. Also, the rising incidence rate of skin disorders across the globe may lead to an increased number of patients who will undergo either invasive or non-invasive skin surgeries. For instance, according to the American Academy of Dermatology in 2013, one in five persons in the US is expected to develop skin disorders in their lifetime.
The biological skin substitutes segment is further classified into allograft (cellular, acellular), xenograft, and amnion. The presence of several acellular skin substitutes in the market is expected to drive the global skin substitutes market. For instance, Alloderm® of LifeCell Inc., Branchburg, NJ, USA, OASIS Wound Matrix of Cook Biotech Inc., West Lafayette, IN, USA, and Integra® DRT (dermal regeneration template) Integra® LifeSciences Corp., USA are some of the acellular skin substitutes prevailing in the market.
Geographical Analysis
North America is growing at the fastest CAGR of 6.6% during the forecast period (2019-2026).
The primary factor contributing to the growth of this market is an increased incidence rate of chronic wounds such as diabetic foot ulcers and pressure ulcers. Furthermore, other factors contributing towards the market growth are a rise in elderly population and technological benefits such as rapid wound healing and reduced chances of infection. An aging population, growing prevalence of chronic wounds, and increased accessibility of healthcare as a result of the Affordable Care Act (ACA) will continue to keep the U.S. well positioned in the global advanced wound care market
The U.S. advanced wound care market also faces multidimensional challenges such as stringent regulatory and economic requirements that are hampering its growth. The U.S. has the highest standards of health care, which is also the costliest in the world. Rising prevalence of chronic wounds such as diabetic foot ulcer, venous ulcers and pressure ulcers (according to CDC estimates, around 2.5 million patients suffer from pressure ulcers every year in the U.S.) creates a large potential population.
According to the National Institutes of Health, more than six million cases of chronic wounds cost $20 billion each year in the United States. Diabetic ulcers, pressure sores, surgical site wounds and traumatic injuries to high-risk patients account for most wounds that won't heal. However, data from a University of Missouri School of Medicine study in February 2017, indicates that a recently developed skin-graft harvesting system aids in chronic wound recovery and reduces care costs by accelerating the healing process.
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com